Medtronic PLC vs Otis Worldwide Corp — how do they compare? Medtronic PLC trades at $88.26 (market cap $112.24B), while Otis Worldwide Corp trades at $66.1 (market cap $25.17B). The key difference: Medtronic PLC is far larger — about 4.5× Otis Worldwide Corp's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Otis Worldwide Corp for 65 Days on average.
| MDT | OTIS | |
|---|---|---|
Market Cap | $112.24B | $25.17B |
Volume | 105,663,236 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $105.35 | $93.62 |
52-Week Low | $73.75 | $64.05 |
Typical Hold Time | 63 Days | 65 Days |
Enterprise Value | $131.58B | $33.20B |
Dividend Yield | 3.28% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Otis Worldwide trades at $65.74, down 1.07% with a bearish technical signal and recent earnings misses. The stock trades near its 52-week low with mixed analyst sentiment (46.7% buy, 46.7% hold) despite a consensus price target of $87.00. Revenue growth remains stable at $14.43B (2025) with 10.17% net margins, though service margins face pressure from labor costs. Recent CEO succession news and China project wins provide strategic context amid weak equipment demand.
The outlook balances stable service revenue against margin pressures and China exposure. Upside exists if service margins recover and modernization backlog converts, but near-term headwinds and technical weakness suggest cautious positioning. Key risks include prolonged China weakness and execution on cost controls.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →